BGSMEDIUM SIGNALFINANCIAL10-K

BGS shows meaningful improvement in net losses alongside declining working capital and operating cash flow generation.

The company substantially reduced its net losses while maintaining share buyback activity, suggesting improved operational efficiency despite some earnings volatility. However, the decline in operating cash flow and reduction in working capital components (receivables and inventory) warrant monitoring for potential demand or operational changes.

Comparing 2026-03-03 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

BGS demonstrated notable financial improvement with net losses substantially reduced from the prior year, though interest expense increased meaningfully to $74.5M. Operating cash flow declined to $101.4M while the company reduced working capital through lower accounts receivable and inventory levels. The combination of improved bottom-line performance alongside reduced working capital suggests either improved efficiency or potentially softer demand conditions requiring careful monitoring.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+82.8%
-$251.3M-$43.3M

Net income grew 82.8% — bottom-line growth signals improving overall business health.

Interest Expense
P&L
+45.6%
$51.1M$74.5M

Interest expense surged 45.6% — significant debt increase or rising rates materially impacting earnings.

Share Buybacks
Cash Flow
+28.9%
$26.9M$34.7M

Share repurchases increased 28.9% — management returning capital, signals confidence in intrinsic value.

Operating Cash Flow
Cash Flow
-22.5%
$130.9M$101.4M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Accounts Receivable
Balance Sheet
-18.3%
$172.3M$140.7M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Inventory
Balance Sheet
-17.7%
$511.2M$420.8M

Inventory reduced 17.7% — lean inventory management or demand outpacing supply.

Stockholders Equity
Balance Sheet
-13.7%
$524.8M$452.9M

Equity decreased 13.7% — buybacks or losses reducing book value, monitor solvency ratios.

Cash & Equivalents
Balance Sheet
+11.3%
$50.6M$56.3M

Cash grew 11.3% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-02-25
ADDED
As of February 26, 2026, the registrant had 79,971,360 shares of common stock outstanding.
Tax Cuts and Jobs Act and the One Big Beautiful Bill Act, and any future tax reform or legislation; our ability to access the credit markets and our borrowing costs and credit ratings, which may be influenced by credit markets generally and the credit ratings of our competitors; unanticipated expenses, including, without limitation, litigation or legal settlement expenses; the effects of currency movements of the Canadian dollar and the Mexican peso as compared to the U.S.
Throughout this report, we refer to our fiscal years ended December 30, 2023, December 28, 2024, January 3, 2026 and January 2, 2027 as fiscal 2023, fiscal 2024, fiscal 2025 and fiscal 2026, respectively.
Fiscal 2026 contains 52 weeks, fiscal 2025 contained 53 weeks, and fiscal 2024 and 2023 each contained 52 weeks.
Each quarter of fiscal 2026 will contain 13 weeks, and the first three quarters of fiscal 2025 and each quarter of fiscal 2024 and fiscal 2023 contained 13 weeks.
+7 more — sign up free →
REMOVED
As of February 20, 2025, the registrant had 79,138,243 shares of common stock outstanding.
Throughout this report, we refer to our fiscal years ended December 31, 2022, December 30, 2023, December 28, 2024 and January 3, 2026 as fiscal 2022, fiscal 2023, fiscal 2024 and fiscal 2025, respectively.
Fiscal 2025 contains 53 weeks, and fiscal 2024, 2023 and 2022 each contained 52 weeks.
Each quarter of fiscal 2024, 2023 and 2022 contained 13 weeks.
In general, we position our products to appeal to the consumer desiring a high quality and reasonably priced product.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →